Letter to the Editor
Leukemia (2006) 20, 154–157. doi:10.1038/sj.leu.2404043; published online 24 November 2005
Maintained immunogenicity of chronic myeloid leukemia-derived dendritic cells in the presence of Imatinib mesylate: implication for vaccination regimens
T M Westers1, J J W M Janssen1, I Houtenbos1, N C L Snoijs1, A A van de Loosdrecht1 and G J Ossenkoppele1
1Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands
Correspondence: TM Westers, E-mail: tm.westers@VUmc.nl
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance
Leukemia Review
Flying under the radar: the new wave of BCR?ABL inhibitors
Nature Reviews Drug Discovery Review (01 Oct 2007)
RESEARCH
Imatinib mesylate does not impair the immunogenicity of human myeloid blood dendritic cells
Leukemia Letter
Bone Marrow Transplantation Original Article
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate
Nature Medicine Article (01 Aug 2006)
